Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma
Status:
Terminated
Trial end date:
2017-10-31
Target enrollment:
Participant gender:
Summary
This randomized pilot phase II trial studies how well giving dalteparin, lenalidomide, and
low-dose dexamethasone together works in treating patients with previously untreated multiple
myeloma. Anticoagulants, such as dalteparin, may help prevent blood clots from forming in
patients being treated with lenalidomide and dexamethasone for multiple myeloma. Biological
therapies, such as lenalidomide, may stimulate the immune system in different ways and stop
cancer cells from growing. Drugs used in chemotherapy, such as dexamethasone, work in
different ways to stop the growth of cancer cells, either by killing the cells or by stopping
them from dividing. Giving dalteparin, lenalidomide, and dexamethasone together may be an
effective treatment for multiple myeloma
Phase:
Phase 2
Details
Lead Sponsor:
University of Southern California
Collaborators:
Celgene Corporation National Cancer Institute (NCI)